Malvyn focuses on specialty pharmaceuticals, including DMARDs, pain management, and nutritionals.
Annual revenue $51,400 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Malvyn

Malvyn is a company. Malvyn offers products and services including DMARDs and Pain Management Medicines.

Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $51.4 K (USD)
    -23.45
    as on Mar 31, 2022
  • Net Profit
    -$7.12 K (USD)
    17.39
    as on Mar 31, 2022
  • EBITDA
    -$1.79 K (USD)
    86.08
    as on Mar 31, 2022
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Malvyn

Malvyn offers a comprehensive portfolio of products and services, including DMARDs and Pain Management Medicines.

Product name locked
Category locked
Primary

DMARDs are employed for slowing the progression of joint damage in rheumatoid arthritis, serving as a key element in treatment plans

Product name locked
Category locked
Locked

A variety of pain management medicines is provided to alleviate suffering and enhance the quality of life for individuals experiencing chronic or acute pain

Funding Insights of Malvyn

Premium access

Detailed funding history for Malvyn

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Malvyn

Investments
Premium access

Investment portfolio details for Malvyn

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Malvyn

Premium access

Detailed financials for Malvyn

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Malvyn Comparisons

Malvyn Primary company
Description
Malvyn focuses on specialty pharmaceuticals, including DMARD...
Location
-
Founded Year
-
Annual Revenue
$51.4 K (USD)
Net Profit
-$7.12 K (USD)
EBITDA
-$1.79 K (USD)
Employees
Not available
Premium access

Peer comparison for Malvyn

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Malvyn

Premium access

Detailed competitors of Malvyn

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Malvyn

Premium access

Complete news archive for Malvyn

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Malvyn

Annual revenue of Malvyn is $51.4K as on Mar 31, 2022.

Malvyn Pharmaceuticals Pvt. Ltd. is recognized as a drug house specializing in the marketing of specialty products, where annual general meetings are conducted to present reports and insights from the CEO and directors. DMARDs are utilized to manage rheumatoid arthritis by slowing joint damage, while a range of pain management medicines is offered to improve quality of life for those with pain conditions. Nutritional products are promoted to address lifestyle disorders through better eating habits across populations. Contact is facilitated via specified email and address in India, ensuring support for product-related queries. All trademarks are acknowledged as property of their owners, with operations centered on healthcare advancements.

Malvyn offers DMARDs and Pain Management Medicines.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available